- Home
- BPTH vs AZTR Comparison
BPTH vs AZTR Comparison
Compare BPTH & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BPTH
- AZTR
- Stock Information
- Founded
- BPTH 2007
- AZTR 2014
- Country
- BPTH United States
- AZTR United States
- Employees
- BPTH N/A
- AZTR N/A
- Industry
- BPTH Biotechnology: Pharmaceutical Preparations
- AZTR Biotechnology: Pharmaceutical Preparations
- Sector
- BPTH Health Care
- AZTR Health Care
- Exchange
- BPTH Nasdaq
- AZTR Nasdaq
- Market Cap
- BPTH 4.0M
- AZTR 4.0M
- IPO Year
- BPTH N/A
- AZTR 2023
- Fundamental
- Price
- BPTH $0.82
- AZTR $0.47
- Analyst Decision
- BPTH Strong Buy
- AZTR
- Analyst Count
- BPTH 2
- AZTR 0
- Target Price
- BPTH $30.00
- AZTR N/A
- AVG Volume (30 Days)
- BPTH 107.7K
- AZTR 161.2K
- Earning Date
- BPTH 11-15-2024
- AZTR 11-12-2024
- Dividend Yield
- BPTH N/A
- AZTR N/A
- EPS Growth
- BPTH N/A
- AZTR N/A
- EPS
- BPTH N/A
- AZTR N/A
- Revenue
- BPTH N/A
- AZTR $97,500.00
- Revenue This Year
- BPTH N/A
- AZTR $494.75
- Revenue Next Year
- BPTH N/A
- AZTR N/A
- P/E Ratio
- BPTH N/A
- AZTR N/A
- Revenue Growth
- BPTH N/A
- AZTR N/A
- 52 Week Low
- BPTH $0.61
- AZTR $0.43
- 52 Week High
- BPTH $12.40
- AZTR $68.40
- Technical
- Relative Strength Index (RSI)
- BPTH 40.36
- AZTR 40.15
- Support Level
- BPTH $0.74
- AZTR $0.43
- Resistance Level
- BPTH $0.85
- AZTR $0.49
- Average True Range (ATR)
- BPTH 0.09
- AZTR 0.04
- MACD
- BPTH -0.01
- AZTR 0.00
- Stochastic Oscillator
- BPTH 53.85
- AZTR 26.44
About BPTH Bio-Path Holdings Inc.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
About AZTR Azitra Inc
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. The company has built a proprietary platform that includes a microbial library comprised of bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen the library of strains for drug-like molecules. The platform also utilizes a licensed genetic engineering technology, which can enable the transformation of previously genetically intractable strains.